Trial Search Results
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
Stanford is currently accepting patients for this trial.
Collaborator: Merck Sharp & Dohme LLC
- Drug: Ertugliflozin
- Drug: Glipizide
Early Phase 1
- patient at Stanford Cardiovascular Surgery clinic who is scheduled for cardiac bypass
- history of Diabetes Mellitus Type 2 currently taking metformin or diet-controlled
- allergy or intolerance to interventional medication
- currently taking any anti-diabetic medication other than metformin
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study